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CASE PRESENTATION
A 6-year-old Korean-American boy was found to have
asymptomatic proteinuria and glycosuria during routine
urinary screening. His birth was complicated by
polyhydramnios. His 4-year-old brother was also found
to have glycosuria and proteinuria on routine urinalysis
(Table 1). There was no history of hematuria, renal failure,
hearing loss, or nephrolithiasis. He was taking no
medications. There was no other family history of renal
disease or renal calculi.
Physical examination revealed a healthy-appearing
young boy with a normal blood pressure of 90/60 mm Hg
and no edema. Physical examination was normal, and
there was no evidence of cataracts, rickets, or mental
retardation. Height and weight were in the 25th
percentiles. Renal ultrasound showed 7.5 cm kidneys with
echogenic medullary regions and one echogenic focus
suggestive of a calculus. Laboratory examination showed
a hematocrit of 34.4% (normal 37–45%), white blood cell
count 10.7 109/L (normal 4.5–13.5 109/L) with normal
differential, platelet count 527 109/L (normal
150–450 109/L), blood urea nitrogen 15 mg/dL
(5.4 mmol/L) (normal 7–18 mg/dL (2.5–6.4 mmol/L)), serum
creatinine 0.3 mg/dL, total serum protein 7.6 g/dL (76 g/L)
(normal 6–8.2 g/dL (60–82 g/L)), serum albumin 4.3 g/dL
(43 g/L) (normal 3.4–5.0 g/dL (34–50 g/L)). The serum
electrolytes, including calcium, magnesium, and
phosphorus were normal. TCO2 was 25.7 mM (normal
22–32 mM). Serologic testing for antinuclear antibody was
negative and the serum complement levels, including C3
and C4, were within normal range. Urinalysis revealed a
specific gravity of 1030, pH 5, protein 4300 mg/dL,
glucose 100 mg/dL, heme moderate, and leukocyte
esterase negative. The urine protein/creatinine ratio was
4.3 and the urine calcium/creatinine ratio was 0.339
(normal o0.200). Urine protein electrophoresis revealed
354 mg/dL of protein of which 26% was albumin with a
large fraction of low molecular weight proteins and a
markedly elevated b2-microglobulin of 159 000mg/dL
(normal 0–300mg/dL). The urinary amino-acid profile
showed no abnormality. Urinary uric acid was 633.6 mg/dL
(normal 250–750 mg/dL), magnesium 54 mg/24 h (normal
12–293 mg/24 h), phosphorus 880 mg/24 h (normal
400–1300 mg/24 h), and copper 32mg/24 h (normal
3–25mg/24 h).
The clinical differential diagnosis included conditions,
both inherited and acquired, that impair proximal
tubular function producing a partial Fanconi syndrome
(glycosuria and low molecular weight proteinuria
(LMWP), without proximal renal tubular acidosis,
aminoaciduria, or hyperphosphaturia). Acquired
conditions to be considered in this age group include
heavy metal toxicity, anti-tubular basement membrane
nephritis, and other forms of interstitial nephritis.
The family history of two affected brothers strongly
suggested an inherited disorder, possibly X-linked or
autosomal recessive. Inherited forms of Fanconi
syndrome to be considered include Dent disease,
Lowe syndrome, cystinosis, and a mitochondriopathy.
In addition, causes of hypercalciuria such as
hyperparathyroidism or excessive calcium intake
were considered, although the absence of hypercalcemia
and the presence of proteinuria argued against
that possibility. Among causes of inherited Fanconi
syndrome, Dent disease is the only form that typically
manifests marked hypercalciuria. A renal biopsy was
performed to determine the cause of the subnephrotic
proteinuria and glycosuria.
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RENAL BIOPSY FINDINGS
Light microscopic examination showed one core of tissue
consisting of renal capsule, full-thickness cortex, and outer
medulla, and one core of inner cortex and medulla. There
were 33 glomeruli, 6 of which were globally sclerotic. Two of
the globally sclerotic glomeruli were located in the immedi-
ately subcapsular region and the other four were located in
the juxtamedullary cortex (Figure 1a). The remaining
glomeruli appeared histologically unremarkable, without
evidence of segmental sclerosis, synechia formation, or
podocyte hypertrophy (Figure 1b). There was a small focus
of tubular atrophy, interstitial fibrosis, and sparse mono-
nuclear interstitial inflammation in the vicinity of three
globally sclerotic juxtamedullary glomeruli, affecting ap-
proximately 5% of the cortex sampled. The cortical tubules
were otherwise unremarkable. In the medulla, there were
multiple collecting ducts distended by voluminous casts
composed of Tamm–Horsfall protein admixed with large
basophilic calcifications, several of which were associated
with giant cell reaction (Figure 1c). A few smaller medullary
interstitial calcifications were also seen. The calcifications did
not polarize but did stain positive with the Von Kossa stain,
indicating that they are composed of calcium phosphate
(Figure 1d). Arteries and arterioles were unremarkable.
The 21 glomeruli sampled for immunofluorescence were
negative for IgG, IgA, C1, fibrinogen, and k- and l-light
chains. There was nonspecific 1þ segmental granular
positivity for IgM and C3 at the vascular pole of two
glomeruli. Ultrastructural evaluation revealed normo-
cellular glomeruli with patent capillaries and unremarkable
mesangium. No glomerular immune-type electron-dense
deposits or endothelial tubuloreticular inclusions were
identified. Glomerular basement membranes appeared nor-
mal in thickness, texture, and contour, without evidence of
thinning or lamellation. There was minimal focal effacement
of foot processes involving approximately 5% of the
glomerular capillary surface area. The proximal tubular
epithelial cells had well-preserved brush borders and
normal-appearing tubular basement membranes. No
dysmorphic mitochondria, intracellular storage material,
or immune deposits were identified involving the tubulo-
interstitial compartment.
The renal biopsy findings were considered nonspecific but
allowed the elimination of many conditions from the
differential diagnosis. First, the immunofluorescence and
ultrastructural findings provided evidence against immune
complex-mediated renal disease and anti-tubular basement
membrane nephritis. The excellent preservation of foot
processes by electron microscopy provided evidence against
undersampled familial focal segmental glomerulosclerosis as
a cause for the subnephrotic proteinuria. The normal
glomerular basement membrane thickness and texture ruled
out hereditary nephritis/Alport syndrome. The absence of
dysmorphic mitochondria ruled out Fanconi syndrome on
the basis of mitochondriopathy. No intracellular crystals or
glycogen accumulation was identified to support Fanconi
syndrome on the basis of cystinosis or Fanconi–Bickel
syndrome, respectively.
The history of LMWP, glycosuria, and hypercalciuria
affecting two brothers strongly favored the possibility of Dent
disease, an X-linked disorder affecting males at a young age
and producing a defect in proximal tubular endosomal
acidification. The presence of numerous medullary tubular
calcifications correlated with the history of hypercalciuria
and presumably represents an early manifestation of the
Table 1 | Laboratory values in two brothers with Dent disease
Proband Brother
Urine
Protein (normal
o150 mg/24 h)
316 mg/24 h 351 mg/24 h
Glucose (normal
0 mg/dL (0 mmol/L))
100 mg/dL
(5.6 mmol /L)
250 mg/dL
(13.9 mmol /L)
Amino acids Normal Normal
b2-Microglobulin
(normal 0–300mg/dL)
159 000mg/dL 91 200mg/dL
Calcium (normal
o4 mg/kg body
weight/24 h)
9.8 mg/kg body
weight/24 h
9.7 mg/kg body
weight/24 h
Copper/creatinine
ratio (normal 0–40)
115 77
Serum
Calcium Normal Normal
Bicarbonate Normal Normal
Potassium Normal Normal
Phosphorus Normal Normal
Renal ultrasound Echogenic Normal
Renal biopsy Focal global
glomerulosclerosis
Not done
a b
c d
Figure 1 | Renal biopsy findings. (a) Two glomeruli in the
juxtamedullary cortex are globally sclerotic. (b) The glomeruli appear
normocellular, without evidence of segmental sclerosis, synechia
formation, or podocyte hypertrophy. (c) Many collecting ducts are
distended by casts composed of Tamm–Horsfall protein admixed
with calcifications. (d) Von Kossa stain is positive in the distribution of
the calcifications, indicating that they are composed of calcium
phosphate.
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nephrolithiasis and nephrocalcinosis typically seen in this
condition. The patient’s family refused genetic testing for the
causative mutation in the CLCN5 gene, but sought a second
opinion from another expert pediatric nephrologist, who
confirmed a clinicopathologic diagnosis of Dent disease.
RENAL BIOPSY DIAGNOSIS
Mild focal global glomerulosclerosis, tubular atrophy, and
interstitial fibrosis with multiple medullary tubular calcifications,
consistent with Dent disease.
DISCUSSION
This patient and his brother have the cardinal phenotypic
features of Dent disease, which include proteinuria, b2-
microglobulinuria, and hypercalciuria. Dent disease (OMIM
300009) is a rare X-linked recessive, Fanconi-like tubulopathy
resulting from genetic defects in CLC-5, a voltage-dependent,
electrogenic chloride/proton exchanger. First described in
1964,1 Dent disease presents in males in childhood or early
adult life with symptoms of LMWP, hypercalciuria, medu-
llary nephrocalcinosis, nephrolithiasis, and progressive
renal failure.2–4 Female carriers often show a less severe
LMWP than male carriers, and rarely demonstrate hyper-
calciuria, depending on X-chromosome inactivation.3,4
However, there may be a family history of renal calculi.5
Other, more variable proximal tubular dysfunctions include
aminoaciduria, glycosuria, and renal phosphate and potas-
sium wasting. Additional complications may include rickets
or osteomalacia.6
In most affected males, total urine protein ranges from 0.5
to 2.5 g per day2–4 but may reach 4 g or higher.2 Less than half
is albumin, and the nephrotic syndrome does not occur.
LMWP is the most consistent and one of the earliest
presenting abnormalities. Urinary b2-microglobulin, a low
molecular weight protein, is excreted in amounts 100–300
times the upper limit of normal. As b2-microglobulin
measurement is readily available, it can be employed as a
practical screening test. Hypercalciuria tends to be modest in
adults, in the range of 4–6 mg per kg body weight per day, but
calcium levels as high as 10 mg per kg body weight per day have
been observed in children.7 Nephrocalcinosis is found in most
patients as early as late childhood or young adulthood, and is
occasionally detected in young children. The onset of renal
insufficiency and progression to end-stage renal disease are
quite variable. Significant loss of glomerular filtration rate can
be seen in childhood, and end-stage renal disease may occur in
the early 30s. Others, however, reach end-stage in their 60s or
later.3,4 The cause of renal failure is not known. Nephrocalci-
nosis, although a common finding, does not correlate
consistently with the presence or degree of renal insufficiency.7
Renal biopsy findings are nonspecific. Biopsies performed
in children may be normal or demonstrate focal global
glomerulosclerosis. Global glomerulosclerosis, tubular atro-
phy, and interstitial scarring without inflammation are
readily identified with disease progression. Nephrocalcinosis
may be significant and is histologically and radiographically
medullary in distribution. Interestingly, ultrastructural stu-
dies do not demonstrate obvious abnormalities in the fine
structure of the proximal tubules, although they are helpful
to exclude other conditions in the differential diagnosis.7,8
Dent disease is caused by mutations in the CLCN5 gene,
which is located on the short arm of the X chromosome
(Xp11.22). The genetic defect was first identified by
positional cloning9 and later characterized and shown to
encode a member of the CLC family of voltage-gated chloride
channels/transporters designated CLC-5.10 Lloyd et al.11
further demonstrated that mutations in the CLCN5 gene
were responsible for the phenotypically similar disorders,
X-linked recessive nephrolithiasis and X-linked recessive
hypophosphatemic rickets. Nakazato et al.12 also demon-
strated CLCN5 mutations in familial idiopathic LMWP in
Japanese patients. They are now collectively referred to as
Dent disease.
More than 80 distinct CLCN5 mutations have been
reported in patients with Dent disease.13 These include
nonsense, missense, frameshift, splice-site, insertional, and
deletional mutations, all of which result in total or near-total
loss of function.7,14 There are no genotype–phenotype
correlations as various mutations are associated with
different clinical phenotypes, even within the same family.13
There is, however, evidence for genetic heterogeneity in Dent
disease. Recently, Hoopes et al.15 reported 13 patients with a
clinical phenotype of Dent disease but lacking CLCN5
mutations. Five of these 13 patients had mutations in
OCRL1, the gene responsible for Lowe syndrome, a multi-
system, pleiotropic disease characterized by Fanconi syn-
drome, progressive renal insufficiency, congenital cataracts,
and mental retardation. OCRL1 encodes a 105-kDa
Golgi protein with phosphatidylinositol-(4,5)-bisphosphate
5-phosphatase activity. Interestingly, each of the five patients
had only mild symptoms of Lowe syndrome.
The chloride/proton exchanger CLC-5 is expressed in the
proximal tubule, the thick ascending limb of Henle, and the
a-intercalated cells of the collecting ducts. In the proximal
tubule cell, CLC-5 localizes predominantly to the intracellular
subapical endosomes, where it colocalizes with the proton
–ATPase responsible for acidifying the lumen of the
endosome.16 Proper acidification is important for endosome
recycling in addition to protein degradation. As a vesicular
chloride/proton exchanger,17 it has been proposed that CLC-
5 allows maximal acidification of the endosome by providing
an electrical shunt to dissipate the positive charge created by
the proton–ATPase pump.18 Low molecular weight proteins
are freely filtered by the glomerulus and reabsorbed by the
proximal tubular epithelium. Thus, the LMWP seen with
CLC-5 dysfunction results from impaired proximal tubular
endocytosis. Immunohistochemical examination of proximal
tubule cells in eight Dent disease cases8 revealed an inverted
polarity of the proton–ATPase, with redistribution to the
basolateral regions, suggesting that the loss of CLC-5 alters
the function of components that codistribute and perhaps
physically interact with it. Electron microscopy demonstrates no
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structural abnormalities in these cases. CLC-5-knockout mouse
models show a phenotype similar to that of Dent disease with
LMWP and phosphaturia.19,20 Detailed studies in these models
reveal impaired endocytosis and a significant reduction of the
proximal tubule cell-surface receptors megalin and cubulin,
which are important for protein uptake.
Studies using CLC-5-knockout mice have helped elucidate
the pathogenesis of LMWP, but the mechanisms by which
CLCN5 mutations cause hypercalciuria, nephrocalcinosis,
and other tubular abnormalities remain unclear. It has been
hypothesized that hypercalciuria, considered a major risk
factor for nephrocalcinosis and nephrolithiasis, results from
an increase in luminal parathyroid hormone as a conse-
quence of a failure to reabsorb filtered parathyroid hormone
in the proximal tubule.19 The high level of parathyroid
hormone in the late proximal tubule should stimulate the
conversion of 25-hydroxy vitamin D3 to the active metabolite
1,25-dihydroxy vitamin D3, which promotes the intestinal
absorption of calcium. This is balanced by the urinary loss of
vitamin D that is not endocytosed with its binding protein.
The two existing CLCN5-knockout models, however, differ
from each other with respect to presence20 or absence19 of
hypercalciuria and nephrocalcinosis. Furthermore, in pa-
tients with proven CLCN5 mutations, as many as 30% do not
demonstrate hypercalciuria on repeated urine analysis, even
though some of these do exhibit nephrocalcinosis.21 This
may be explained by the observation that CLC-5 disruption
promotes calcium crystal agglomeration, as well as a
redistribution of the crystal-binding molecule annexin A2,
in collecting duct epithelial cells in vitro.22
This case illustrates that the possibility of Dent disease
should always be considered in a child with subnephrotic
proteinuria and mild focal global glomerulosclerosis who
lacks foot process effacement or other pathologic evidence of
primary glomerular disease.5 Medullary calcifications are a
helpful morphologic clue to the diagnosis in a patient with or
without evidence of nephrolithiasis and should lead to an
evaluation for hypercalciuria and Fanconi syndrome. Because
the disease is X-linked, it is important to obtain a careful
family history of renal calculi in otherwise unaffected
mothers and to evaluate apparently normal brothers. Patients
with Dent disease may progress to end-stage renal disease.
Therefore, we advise treatment with citrate buffer to reduce
the risk of nephrocalcinosis and nephrolithiasis based on the
observation that there was significantly delayed progression
of renal disease in CLC-5-knockout mice fed high citrate
diets.23 It is possible that the citrate may also reduce the
development of renal calculi and nephrocalcinosis. Thiazides
also have been reported to correct the hypercalciuria in
patients with Dent disease,24 in doses similar to effective
doses for idiopathic hypercalciuria, presumably by
stimulating the reabsorption of calcium in the distal
convoluted tubule, where CLC-5 is not expressed. In
addition, we recommend treatment with an angiotensin-
converting enzyme inhibitor or angiotensin receptor blocker
to allay progression.5
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